|
|
|||
|
|||
|
|
|||
|
cat food allergies |
|||
|
|
|||
|
|||
 
|
|||
|
|
|||
|
cat food allergies DESCRIPTION Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist(LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide cat food allergies. The molecular weight of zafirlukast is 575.7 and the structural formula is:
Zafirlukast, a fine white to pale yellow amorphous powder, is practically insolublein water cat food allergies. It is slightly soluble in methanol and freely soluble in tetrahydrofuran,dimethylsulfoxide, and acetone cat food allergies. ACCOLATE is supplied as 10 and 20 mg tablets for oral administration cat food allergies. Inactive Ingredients: Film-coated tablets containing croscarmellose sodium,lactose, magnesium stearate, microcrystalline cellulose, povidone, hypromellose,and titanium dioxide cat food allergies.
In vitro studies demonstrated that zafirlukast antagonized the contractileactivity of three leukotrienes (LTC 4 , LTD 4 and LTE 4 ) in conducting airwaysmooth muscle from laboratory animals and humans cat food allergies. Zafirlukast prevented intradermalLTD 4 -induced increases in cutaneous vascular permeability and inhibited inhaledLTD 4 -induced influx of eosinophils into animal lungs cat food allergies. Inhalational challengestudies in sensitized sheep showed that zafirlukast suppressed the airway responsesto antigen; this included both the early- and late-phase response and the nonspecifichyperresponsiveness cat food allergies. In humans, zafirlukast inhibited bronchoconstriction caused by several kindsof inhalational challenges cat food allergies. Pretreatment with single oral doses of zafirlukastinhibited the bronchoconstriction caused by sulfur dioxide and cold air in patientswith asthma cat food allergies. Pretreatment with single doses of zafirlukast attenuated the early-and late-phase reaction caused by inhalation of various antigens such as grass,cat dander, ragweed, and mixed antigens in patients with asthma cat food allergies. Zafirlukastalso attenuated the increase in bronchial hyperresponsiveness to inhaled histaminethat followed inhaled allergen challenge cat food allergies. Clinical Pharmacokinetics and Bioavailability: Distribution Metabolism Excretion In the pivotal bioequivalence study, the mean terminal half-life of zafirlukastis approximately 10 hours in both normal adult subjects and patients with asthma cat food allergies. In other studies, the mean plasma half-life of zafirlukast ranged from approximately8 to 16 hours in both normal subjects and patients with asthma cat food allergies. The pharmacokineticsof zafirlukast are approximately linear over the range from 5 mg to 80 mg cat food allergies. Steady-stateplasma concentrations of zafirlukast are proportional to the dose and predictablefrom single-dose pharmacokinetic data cat food allergies. Accumulation of zafirlukast in the plasmafollowing twice-daily dosing is approximately 45% cat food allergies. The pharmacokinetic parameters of zafirlukast 20 mg administered as a singledose to 36 male volunteers are shown with the table below cat food allergies. Mean (% Coefficient of Variation) pharmacokinetic
Race: No differences in the pharmacokinetics of zafirlukast due to race havebeen observed cat food allergies. Elderly: The apparent oral clearance of zafirlukast decreases with age cat food allergies. Inpatients above 65 years of age, there is an approximately 2-3 fold greater Cmax and AUC compared to young adult patients cat food allergies. Children: Following administration of a single 20 mg dose of zafirlukast to20 boys and girls between 7 and 11 years of age, and in a second study, to 29boys and girls between 5 and 6 years of age, the following pharmacokinetic parameterswere obtained: Parameter Children age
Zafirlukast disposition was unchanged after multiple dosing (20 mg twice daily)in children and the degree of accumulation in plasma was similar to that observedin adults cat food allergies. Hepatic Insufficiency: In a study of patients with hepatic impairment (biopsy-provencirrhosis), there was a reduced clearance of zafirlukast resulting in a 50-60%greater C max and AUC compared to normal subjects cat food allergies. Renal Insufficiency: Based on a cross-study comparison, there are no apparentdifferences in the pharmacokinetics of zafirlukast between renally-impairedpatients and normal subjects cat food allergies. Drug-Drug Interactions
|
|||
 
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| ccat food allergies caat food allergies catt food allergies cat food allergies cat ffood allergies cat foood allergies cat foood allergies cat foodd allergies cat food allergies cat food aallergies cat food alllergies cat food alllergies cat food alleergies cat food allerrgies cat food allerggies cat food allergiies cat food allergiees cat food allergiess at food allergies ct food allergies ca food allergies catfood allergies cat ood allergies cat fod allergies cat fod allergies cat foo allergies cat foodallergies cat food llergies cat food alergies cat food alergies cat food allrgies cat food allegies cat food alleries cat food allerges cat food allergis cat food allergie c at food allergies ca t food allergies cat food allergies cat food allergies cat f ood allergies cat fo od allergies cat foo d allergies cat food allergies cat food allergies cat food a llergies cat food al lergies cat food all ergies cat food alle rgies cat food aller gies cat food allerg ies cat food allergi es cat food allergie s cat food allergies act food allergies cta food allergies ca tfood allergies catf ood allergies cat ofod allergies cat food allergies cat fodo allergies cat foo dallergies cat fooda llergies cat food lalergies cat food allergies cat food alelrgies cat food allregies cat food allegries cat food alleriges cat food allergeis cat food allergise acat food allergies thecat food allergies cat food allergies | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |
